Clinical evidence shows that intraocular hypertension is not the primary pathogenetic event
of glaucoma, whereas early neurodegeneration of retinal ganglion cells (RGCs) represents …

Glaucoma etiology often includes retinal ganglion cell (RGC) death associated with elevated
intraocular pressure (IOP). However, even when IOP is managed well, disease can …

In recent years the focus of glaucoma research has shifted toward neuroprotection, as the
traditional strategies of lowering intraocular pressure have been shown to be unable to …

Neuroprotection in glaucoma is any medical treatment by which decline in visual function
can be slowed or prevented by supporting the health and survival of neural cells …

Background: Glaucoma is characterized as a neuropathic disease that causes progressive
degeneration of retinal ganglion cells (RGCs) in the retina, resulting in irreversible loss of …

Glaucoma is an optic neuropathy, specifically a neurodegenerative disease characterized
by loss of retinal ganglion cells (RGCs) and their axons. The pathogenesis of RGC loss in …

In the last years, neuroprotective therapies have attracted the researcher interests as
modern and challenging approach for the treatment of neurodegenerative diseases, aimed …

Glaucoma is the second leading cause of blindness worldwide and is most notably
characterized by progressive optic nerve atrophy and advancing loss of retinal ganglion …

Glaucoma, the leading cause globally of irreversible blindness, is a neurodegenerative
disease characterized by progressive retinal ganglion cell death. To date, no drug has been …

Progressive neurodegeneration of the optic nerve and the loss of retinal ganglion cells is a
hallmark of glaucoma, the leading cause of irreversible blindness worldwide, with primary …